Antithrombotic drugs for carotid artery dissection

Area of Science:

• Neurology
• Vascular Medicine
• Clinical Trials

Background:

• Extracranial internal carotid artery dissection is a cause of ischemic stroke, particularly in younger adults.
• It accounts for approximately 2.5% of all strokes.
• Antithrombotic treatments carry risks of bleeding, necessitating careful evaluation of their benefits and safety.

Purpose of the Study:

• To evaluate the efficacy and safety of antithrombotic drugs (antiplatelet and anticoagulation) for treating extracranial internal carotid artery dissection.
• To determine the optimal antithrombotic treatment strategy.

Main Methods:

• Searched multiple databases including Cochrane Stroke Group Trials Register, Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE.
• Included randomized controlled trials, controlled clinical trials, and non-randomized studies (case series) with at least 4 patients.
• Extracted data on primary outcomes (death, death or disability) and secondary outcomes (stroke, hemorrhage).

Main Results:

• No randomized trials were identified, thus no reliable comparisons with control groups.
• Twenty-six non-randomized studies with 327 patients were analyzed.
• No significant difference in mortality or death/disability was found between antiplatelet drugs and anticoagulants. Few intracranial hemorrhages were reported with anticoagulants.

Conclusions:

• Lack of randomized trials means no evidence supports routine use of anticoagulants or antiplatelet drugs for extracranial internal carotid artery dissection.
• Non-randomized studies did not demonstrate a significant difference between these treatments.
• A large-scale randomized trial with at least 1400 patients per arm is recommended.